Top broker tips Australian Clinical Labs (ASX:ACL) share price to shoot higher

This broker thinks ASX investors should get better acquainted with this ASX share…

| More on:
A young man pointing up looking amazed, indicating a surging share price movement for an ASX company

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Australian Clinical Labs Ltd (ASX: ACL) share price is pushing higher on Monday.

In afternoon trade, the pathology services provider's shares are up 2% to $3.76.

Despite this gain, the Australian Clinical Labs share price is still trading 6% below its May IPO price of $4.00.

Why is the Australian Clinical Labs share price pushing higher?

Investors have been buying the company's shares this morning following the release of a bullish broker note out of Goldman Sachs.

According to the note, the broker has initiated coverage on the company with a buy rating and $4.80 price target. Based on the current Australian Clinical Labs share price, this implies potential upside of almost 28% over the next 12 months.

Goldman Sachs was the joint lead manager and underwriter of the company's IPO last month.

What did Goldman Sachs say?

Goldman believes that Australian Clinical Labs will benefit from a series of operational investments. These include its unified Laboratory Information System and upgraded central laboratory network.

In addition to this, over the long term, the broker expects the company's growth to track around market growth of 3% to 5%. However, it sees scope for the company to achieve the upper end of this range if it executes well on growth strategies in New South Wales and Queensland.

Furthermore, it notes that with leverage of 1.0x net debt/EBITDA, there is the opportunity to accelerate its growth through acquisitions.

Attractive valuation

Another reason to be positive on the Australian Clinical Labs share price is its valuation. Particularly in comparison to rivals Healius Ltd (ASX: HLS) and Sonic Healthcare Limited (ASX: SHL).

Goldman commented: "We believe current trading multiples are undemanding: FY22E EV/EBITDA 6.8x (vs. HLS 9.1x; SHL 11.3x) and FY22E EV/EBIT: 16.2x (vs. HLS 20.1x; SHL 17.6x)."

"Whilst the forward EBIT growth profile of +4% (FY22-25E) is less attractive than HLS (+7%), it is above SHL (+2%), and hence in-line with the peer average. ASX 200 HC [healthcare sector] trades on 21x EBITDA for +8% CAGR," it added.

This could make it worth considering if you're looking for healthcare options.

James Mickleboro does not own any shares mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Bored man sitting at his desk with his laptop.
Share Fallers

Why Antipa Minerals, Northern Star, Pilbara Minerals, and Synlait Milk shares are falling today

These shares are starting the week in the red. But why?

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Share Gainers

Why Bellevue Gold, Cobram, Hub24, and Nanosonics shares are pushing higher

These shares are starting the week on a positive note. But why?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »

Broker analysing the share price.
Materials Shares

Buy, hold, or sell? Broker's verdict on 3 ASX 200 materials shares

Materials was one of four market sectors that weakened in overall value in FY25.

Read more »

Percentage sign on a blue graph representing interest rates.
Share Market News

Will ASX 200 investors get a supersized RBA interest rate cut tomorrow?

The ASX 200 could make some big moves tomorrow on any unexpected RBA interest rate announcement.

Read more »

A person sitting at a desk smiling and looking at a computer.
Technology Shares

3 ASX 200 tech shares to buy in July: Experts

The ASX tech sector delivered outstanding returns for investors in FY25.

Read more »

Falling yellow arrow with descending wooden bars with the percentage sign written on them.
Share Market News

How much cash will the average mortgage holder save if the RBA cuts interest rates tomorrow?

And how to best redeploy those funds?

Read more »

most shorted shares webjet
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »